Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
NCT07157631
Summary
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is non-inferior to placebo for a composite of thrombotic events within the initial 7 postoperative days. Secondarily, we will determine whether tranexamic acid is superior to placebo on total postoperative drainage volume and blood product transfusion within the initial 3 postoperative days. We propose to randomize patients to 2.0 g of tranexamic acid intravenously at the start of surgery or a comparable volume of 0.9% normal saline placebo. Because demonstrating safety will require more patients, our sample size is based on safety. Randomizing 1546 patients will provide 80% power for detecting a non-inferiority margin of 4% with a baseline incidence of 10% for composite thrombotic events within the initial 7 postoperative days.
Eligibility
Inclusion Criteria:consenting adults aged at least 18 years who are scheduled for allogeneic liver transplantation with general anesthesia. \- Exclusion Criteria:1) History of arterial or venous thrombosis within 3 months; 2) Re-transplantation; 3) Known allergy to tranexamic acid; 4) Participation in potentially conflicting clinical trials; 5) Considered by the responsible surgeon or anesthesiologist to be unsuitable. \-
Conditions4
Interventions2
Related trials
- Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts — First Hospital of China Medical University
- Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia — University of Manitoba
- Perioperative Treatment With Tranexamic Acid in Melanoma — University of Aarhus
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) — Ottawa Hospital Research Institute
- Tranexamic Acid During Colonic Endoscopic Resection Procedures — Assaf-Harofeh Medical Center
- Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients — Second Affiliated Hospital, School of Medicine, Zhejiang University
- The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients — Stanford University
- A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients — M.D. Anderson Cancer Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07157631